Physician profile
Michael W Verser
NPI 1124095120
$821.04
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $172 · 2021: $412 · 2022: $74.27.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $101.11 | 2021-2022 | |
| Pfizer INC. | $93.90 | 2019-2021 | |
| Allergan, INC. | $84.49 | 2019-2020 | |
| Lilly USA, LLC | $81.87 | 2020-2021 | |
| Glaxosmithkline, LLC. | $81.41 | 2019-2022 | |
| Kyowa Kirin, INC. | $74.11 | 2021 | |
| Amgen INC. | $48.07 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.96 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $29.08 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $28.94 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $27.23 | 2019 | |
| Novartis Pharmaceuticals Corporation | $26.74 | 2019-2021 | |
| Abbott Laboratories | $23.43 | 2021 | |
| Supernus Pharmaceuticals, INC. | $19.60 | 2021 | |
| Genentech USA, INC. | $16.26 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $15.37 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.91 | 2021 | |
| Novo Nordisk INC | $12.56 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Verser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.